Journal article
Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
- Abstract:
-
Although treatment of multiple myeloma (MM) with daratumumab significantly extends the patient's lifespan, resistance to therapy is inevitable. ISB 1342 was designed to target MM cells from patients with relapsed/refractory MM (r/r MM) displaying lower sensitivity to daratumumab. ISB 1342 is a bispecific antibody with a high-affinity Fab binding to CD38 on tumor cells on a different epitope than daratumumab and a detuned scFv domain affinity binding to CD3ε on T cells, to mitigate the risk of...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 2.3MB, Terms of use)
-
- Publisher copy:
- 10.1182/blood.2022019451
Authors
Bibliographic Details
- Publisher:
- American Society of Hematology
- Journal:
- Blood More from this journal
- Volume:
- 142
- Issue:
- 3
- Pages:
- 260-273
- Place of publication:
- United States
- Publication date:
- 2023-05-16
- Acceptance date:
- 2023-05-01
- DOI:
- EISSN:
-
1528-0020
- ISSN:
-
0006-4971
- Pmid:
-
37192303
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
1343875
- Local pid:
-
pubs:1343875
- Deposit date:
-
2024-04-23
Terms of use
- Copyright holder:
- The American Society of Hematology
- Copyright date:
- 2023
- Rights statement:
- © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record